• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球、区域和国家良性前列腺增生发病率和 1990 年至 2019 年残疾年数。

Global, Regional, and National Incidence and Year Lived with Disability for Benign Prostatic Hyperplasia from 1990 to 2019.

机构信息

Department of Urology, Xianyang Central Hospital, Xianyang, China.

Clinical Research Center of Xianyang City, Xianyang Central Hospital, Xianyang, China.

出版信息

Am J Mens Health. 2021 Jul-Aug;15(4):15579883211036786. doi: 10.1177/15579883211036786.

DOI:10.1177/15579883211036786
PMID:34330182
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8326634/
Abstract

The objective of this study is to provide comprehensive and up-to-date estimates on the disease burden of BPH in 204 countries and territories between 1990 and 2019. Data about incidence, year lived with disability (YLD), and their age-standardized rates (ASRs) for 21 regions, 5 Socio-demographic Index (SDI) quintiles, 204 countries and territories, and 12 age categories from 1990 to 2019 were obtained from the Global Burden of Disease 2019 study. Estimated annual percentage changes (EAPCs) of the ASRs and the associations between SDI and the ASRs were estimated. The effects of population growth, population aging, and age-specific rate on the changes in the absolute numbers of incidence and YLD were quantified. Globally, there were 11.26 million (95% uncertainty interval [UI]: 8.79, 14.46) new cases and 1.86 million (95%UI: 1.13, 2.78) YLD due to BPH in 2019. The global ASRs of incidence (EAPC: -0.031, 95% CI: -0.050, -0.012) and YLD (EAPC: -0.058, 95% CI: -0.084, -0.031) decreased slightly from 1990 to 2019, whereas the absolute numbers increased dramatically from 1990 (incidence by 105.7% and YLD by 110.6%), mainly driven by the population growth (53.5% for incidence and 54.4% for YLD) and population aging (55.7% for incidence and 63.2% for YLD). The burden of BPH varied markedly among different regions, socioeconomic status, and countries. As the population is growing and aging, great efforts are required to develop effective prevention, treatment and management strategies to meet the high and increasing burden of BPH worldwide.

摘要

本研究旨在提供 1990 年至 2019 年期间 204 个国家和地区 BPH 疾病负担的综合且最新估计值。关于发病率、残疾年数(YLD)及其在 21 个地区、5 个社会人口指数(SDI)五分位数、204 个国家和地区以及 12 个年龄组的年龄标准化率(ASR)的数据,来自 2019 年全球疾病负担研究。估计了 ASR 的年估计百分比变化(EAPC)以及 SDI 与 ASR 之间的关联。量化了人口增长、人口老龄化和特定年龄组对发病率和 YLD 绝对数量变化的影响。全球范围内,2019 年有 1126 万(95%置信区间 [95%CI]:879 万,1446 万)新病例和 186 万(95%CI:113 万,278 万)与 BPH 相关的 YLD。1990 年至 2019 年,发病率(EAPC:-0.031,95%CI:-0.050,-0.012)和 YLD(EAPC:-0.058,95%CI:-0.084,-0.031)的全球 ASR 略有下降,而绝对值却从 1990 年开始大幅增加(发病率增加 105.7%,YLD 增加 110.6%),这主要是由人口增长(发病率 53.5%,YLD 54.4%)和人口老龄化(发病率 55.7%,YLD 63.2%)驱动的。BPH 的负担在不同地区、社会经济地位和国家之间差异显著。随着人口的增长和老龄化,需要做出巨大努力来制定有效的预防、治疗和管理策略,以应对全球范围内 BPH 负担的增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f384/8326634/ba61480f4c18/10.1177_15579883211036786-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f384/8326634/75473aecb42e/10.1177_15579883211036786-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f384/8326634/ecc8530fceaf/10.1177_15579883211036786-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f384/8326634/ba61480f4c18/10.1177_15579883211036786-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f384/8326634/75473aecb42e/10.1177_15579883211036786-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f384/8326634/ecc8530fceaf/10.1177_15579883211036786-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f384/8326634/ba61480f4c18/10.1177_15579883211036786-fig3.jpg

相似文献

1
Global, Regional, and National Incidence and Year Lived with Disability for Benign Prostatic Hyperplasia from 1990 to 2019.全球、区域和国家良性前列腺增生发病率和 1990 年至 2019 年残疾年数。
Am J Mens Health. 2021 Jul-Aug;15(4):15579883211036786. doi: 10.1177/15579883211036786.
2
Prevalence, Incidence, and Years Lived With Disability Due to Gout and Its Attributable Risk Factors for 195 Countries and Territories 1990-2017: A Systematic Analysis of the Global Burden of Disease Study 2017.1990-2017 年全球 195 个国家和地区痛风的患病率、发病率及伤残调整寿命年(因痛风导致的失能)及其归因危险因素分析:基于 2017 年全球疾病负担研究的系统分析
Arthritis Rheumatol. 2020 Nov;72(11):1916-1927. doi: 10.1002/art.41404. Epub 2020 Sep 10.
3
Secular Trends in Musculoskeletal Rehabilitation Needs in 191 Countries and Territories From 1990 to 2019.1990 年至 2019 年 191 个国家和地区肌肉骨骼康复需求的长期趋势。
JAMA Netw Open. 2022 Jan 4;5(1):e2144198. doi: 10.1001/jamanetworkopen.2021.44198.
4
The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.2000 年至 2019 年全球 204 个国家和地区良性前列腺增生的全球、区域和国家负担:2019 年全球疾病负担研究的系统分析。
Lancet Healthy Longev. 2022 Nov;3(11):e754-e776. doi: 10.1016/S2666-7568(22)00213-6. Epub 2022 Oct 20.
5
Global incidence, prevalence, and disability of vertebral fractures: a systematic analysis of the global burden of disease study 2019.全球椎体骨折的发病率、患病率和残疾负担:2019 年全球疾病负担研究的系统分析。
Spine J. 2022 May;22(5):857-868. doi: 10.1016/j.spinee.2021.12.007. Epub 2021 Dec 11.
6
Trends in the prevalence and disability-adjusted life years of eating disorders from 1990 to 2017: results from the Global Burden of Disease Study 2017.1990 年至 2017 年饮食失调症的流行趋势和残疾调整生命年数:2017 年全球疾病负担研究结果。
Epidemiol Psychiatr Sci. 2020 Dec 7;29:e191. doi: 10.1017/S2045796020001055.
7
Global, regional, and national burden of premenstrual syndrome, 1990-2019: an analysis based on the Global Burden of Disease Study 2019.全球、区域和国家经前期综合征负担,1990-2019 年:基于 2019 年全球疾病负担研究的分析。
Hum Reprod. 2024 Jun 3;39(6):1303-1315. doi: 10.1093/humrep/deae081.
8
Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019.基于 2019 年全球疾病负担研究的中、美良性前列腺增生负担比较。
World J Urol. 2023 Dec;41(12):3629-3634. doi: 10.1007/s00345-023-04658-8. Epub 2023 Oct 13.
9
Global, regional, and national burden of infertility attributable to PCOS, 1990-2019.全球、区域和国家多囊卵巢综合征所致不孕负担,1990-2019 年。
Hum Reprod. 2024 Jan 5;39(1):108-118. doi: 10.1093/humrep/dead241.
10
Global burden of benign prostatic hyperplasia in males aged 60-90 years from 1990 to 2019: results from the global burden of disease study 2019.2019 年全球疾病负担研究:1990 年至 2019 年 60-90 岁男性良性前列腺增生的全球负担。
BMC Urol. 2024 Sep 5;24(1):193. doi: 10.1186/s12894-024-01582-w.

引用本文的文献

1
The relationship between the triglyceride glucose-waist height ratio and benign prostatic hyperplasia in middle-aged and elderly adults: a nationwide cohort study.中老年人群中甘油三酯葡萄糖-腰围身高比与良性前列腺增生的关系:一项全国性队列研究
BMC Urol. 2025 Jul 3;25(1):153. doi: 10.1186/s12894-025-01844-1.
2
Hydroxycitric acid inhibits ferroptosis and ameliorates benign prostatic hyperplasia by upregulating the Nrf2/GPX4 pathway.羟基柠檬酸通过上调Nrf2/GPX4通路抑制铁死亡并改善良性前列腺增生。
World J Urol. 2025 May 20;43(1):318. doi: 10.1007/s00345-025-05637-x.
3
Association between TyG-BMI and BPH in a national prospective cohort study.

本文引用的文献

1
A potential therapeutic strategy for prostatic disease by targeting the oral microbiome.靶向口腔微生物组治疗前列腺疾病的潜在治疗策略。
Med Res Rev. 2021 May;41(3):1812-1834. doi: 10.1002/med.21778. Epub 2020 Dec 30.
2
The rising worldwide impact of benign prostatic hyperplasia.良性前列腺增生症在全球范围内的影响日益增加。
BJU Int. 2021 Jun;127(6):722-728. doi: 10.1111/bju.15286. Epub 2020 Nov 21.
3
Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
一项全国性前瞻性队列研究中TyG-BMI与良性前列腺增生的关联。
Sci Rep. 2025 Mar 13;15(1):8743. doi: 10.1038/s41598-024-81629-y.
4
Global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021 and projection to 2035.1990年至2021年全球、区域和国家良性前列腺增生症负担及到2035年的预测。
BMC Urol. 2025 Feb 19;25(1):34. doi: 10.1186/s12894-025-01715-9.
5
Comprehensive analysis of the global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021.1990年至2021年全球、区域和国家良性前列腺增生负担的综合分析。
Sci Rep. 2025 Feb 15;15(1):5644. doi: 10.1038/s41598-025-90229-3.
6
Association between the Chinese Visceral Adiposity Index and the risk of Benign Prostatic Hyperplasia: a national prospective cohort study.中国内脏脂肪素指数与良性前列腺增生风险之间的关联:一项全国性前瞻性队列研究。
Sci Rep. 2025 Jan 2;15(1):222. doi: 10.1038/s41598-024-83960-w.
7
Cucurbitacin B Inhibits the Proliferation of WPMY-1 Cells and HPRF Cells via the p53/MDM2 Axis.葫芦素 B 通过 p53/MDM2 轴抑制 WPMY-1 细胞和 HPRF 细胞的增殖。
Int J Mol Sci. 2024 Aug 28;25(17):9333. doi: 10.3390/ijms25179333.
8
Awareness and prevalence of self-reported benign prostatic hyperplasia: a cross-sectional study in Saudi Arabia.自我报告良性前列腺增生症的知晓率和流行率:沙特阿拉伯的一项横断面研究。
Front Public Health. 2024 Apr 2;12:1271816. doi: 10.3389/fpubh.2024.1271816. eCollection 2024.
9
Association between chronic prostatitis and the subsequent benign prostatic hyperplasia: a population-based national cohort study.慢性前列腺炎与良性前列腺增生症的相关性:基于人群的全国队列研究。
World J Urol. 2024 Mar 9;42(1):126. doi: 10.1007/s00345-024-04820-w.
10
The Burden of Urologic Diseases in a Tertiary Hospital in South-eastern Nigeria: A Three-Year Review.尼日利亚东南部一家三级医院的泌尿系统疾病负担:三年回顾
J West Afr Coll Surg. 2023 Oct-Dec;13(4):78-82. doi: 10.4103/jwas.jwas_59_23. Epub 2023 Sep 16.
204 个国家和地区 1990-2019 年 369 种疾病和伤害导致的全球负担:2019 年全球疾病负担研究的系统分析。
Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9.
4
Benign prostatic hyperplasia - what do we know?良性前列腺增生症——我们了解多少?
BJU Int. 2021 Apr;127(4):389-399. doi: 10.1111/bju.15229. Epub 2020 Sep 24.
5
Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends.2 型糖尿病的流行病学——全球疾病负担和预测趋势。
J Epidemiol Glob Health. 2020 Mar;10(1):107-111. doi: 10.2991/jegh.k.191028.001.
6
Periodontal disease and risk of benign prostate hyperplasia: a cross-sectional study.牙周病与良性前列腺增生症的关系:一项横断面研究。
Mil Med Res. 2019 Nov 13;6(1):34. doi: 10.1186/s40779-019-0223-8.
7
Body Mass Index and Risk of Prostate Volume, International Prostate Symptom Score, Maximum Urinary Flow Rate, and Post-Void Residual in Benign Prostatic Hyperplasia Patients.体重指数与良性前列腺增生患者前列腺体积、国际前列腺症状评分、最大尿流率和剩余尿量的风险。
Am J Mens Health. 2019 Jul-Aug;13(4):1557988319870382. doi: 10.1177/1557988319870382.
8
Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in China: results from the China Health and Retirement Longitudinal Study.中国良性前列腺增生症(LUTS/BPH)下尿路症状患病率:来自中国健康与养老追踪调查的结果。
BMJ Open. 2019 Jun 19;9(6):e022792. doi: 10.1136/bmjopen-2018-022792.
9
The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention.特定病因引起的原发性肝癌发病率趋势:2016 年全球疾病负担研究结果及其对肝癌预防的意义。
J Hepatol. 2019 Apr;70(4):674-683. doi: 10.1016/j.jhep.2018.12.001. Epub 2018 Dec 11.
10
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.全球、区域和国家 84 种行为、环境、职业和代谢风险以及 195 个国家和地区 1990 至 2017 年风险簇的比较风险评估:全球疾病负担研究 2017 系统分析。
Lancet. 2018 Nov 10;392(10159):1923-1994. doi: 10.1016/S0140-6736(18)32225-6. Epub 2018 Nov 8.